Legend Biotech CORP Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Peter Salovey, a Director of Legend Biotech Corp, received 28,330 shares of common stock on September 24, 2026.
NASDAQ
Tomas J. Heyman, a Director of Legend Biotech Corp, received 20,986 shares of common stock on September 24, 2026.
NASDAQ
Li Mao, a Director of Legend Biotech Corp, received 20,986 shares of common stock on September 24, 2026.
NASDAQ
Patrick John Casey, a Director of Legend Biotech Corp, received 20,986 shares of common stock on September 24, 2026.
NASDAQ
Darren Xiaohui Ji, a Director of Legend Biotech Corp, received 28,330 shares of common stock on September 24, 2026.
NASDAQ
Corazon (Corsee) D. Sanders, a Director of Legend Biotech Corp, received 20,986 shares of common stock on September 24, 2026.
NASDAQ
Form 4: Legend Biotech CFO Sells Shares
Carlos E Santos, Chief Financial Officer of Legend Biotech Corp, sold 5,430 shares of common stock on September 21, 2026 for $9.14 per share.
NASDAQ
Ingrid Zhang, Chief Executive Officer of Legend Biotech Corp, received 1,131,860 shares of common stock on September 15, 2026.
NASDAQ
Legend Biotech Corp. Director Patrick John Casey reported a sale of 6,000 ordinary shares on June 30, 2026, for a total transaction value of $88,800.
NASDAQ
Form 4: Legend Biotech CEO Sells Shares
Legend Biotech Corp. CEO Ying Huang reported a sale of 5,566 ordinary shares on June 25, 2026, to cover tax obligations.
NASDAQ
Legend Biotech Corp's CEO, Huang Ying, sold 9,936 ordinary shares to cover tax obligations related to restricted share unit vesting.